Brian Mazzarella, MD
Urology · Lakeway, TXNPI 1417265851
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Neotract Inc. accounts for 65.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2020 at $401,987 and has fallen 97.8% since, to $8,748 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,089 payments — averaging $1078.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$764K
- Teleflex LLC$310K
- Calyxo, Inc.$43K
- Teleflex Medical Australia Pty Ltd$27K
- Palette Life Sciences, Inc.$16K
- Janssen Global Services, LLC$3K
- plus $11K from 28 others
Across 270 payments — averaging $12,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2M
- AstraZeneca$508K
- Pfizer$332K
- Sumitomo Pharma America, Inc.$198K
- Neotract Inc.$80K
- Calyxo, Inc.$71K
- plus $97K from 5 others
What the payments were for
- Consulting fees$505,43343%
- Speaking & faculty fees$541,89446%
- Grants$40,0003%
- Travel & lodging$68,3466%
- Food & beverage$18,2912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 672 | $764,418 |
| Teleflex LLC | 309 | $309,757 |
| Calyxo, Inc. | 7 | $43,263 |
| Teleflex Medical Australia Pty Ltd | 4 | $26,934 |
| Palette Life Sciences, Inc. | 11 | $15,862 |
| Janssen Global Services, LLC | 4 | $3,191 |
| Janssen Scientific Affairs, LLC | 9 | $2,750 |
| Laborie Medical Technologies Corp. | 2 | $2,594 |
| AstraZeneca | 5 | $2,537 |
| Johnson & Johnson | 13 | $756 |
| Medtronic | 3 | $357 |
| Biotissue Holdings Inc. | 3 | $318 |
| Boston Scientific | 9 | $295 |
| Bayer | 6 | $166 |
| Procept Biorobotics Corporation | 4 | $112 |
| Ferring Pharmaceuticals Inc. | 1 | $102 |
| Dendreon Pharmaceuticals LLC | 2 | $69 |
| Novartis | 3 | $62 |
| Merck | 2 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Telix Pharmaceuticals | 1 | $34 |
| Endo Pharmaceuticals Inc. | 2 | $32 |
| Endo USA, Inc. | 2 | $31 |
| Foundation Medicine, Inc. | 1 | $25 |
| Urogen Pharma, Inc. | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| AbbVie | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Blue Earth Diagnostics | 1 | $17 |
| Pfizer | 1 | $15 |
| Coloplast | 1 | $14 |
| Tempus AI, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$859,344
- UroLift System$222,292
- CVAC$41,757
- Optilume BPH Drug Coated Balloon Catheter$2,594
- IMFINZI$1,517
- CVAC Aspiration System$1,413
- UroLift 2 System$840
- Erleada$640
- NEOX$280
- CLARIX$280
- INTERSTIM$279
- Balversa$138
- RYBREVANT$114
- CARVYKTI$114
- ADSTILADRIN$102
How this compares
$1,173,963 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 13 | $166 |
| Finasteride | 11 | $166 |
Paid to pharmacies, not to this prescriber.
Other urology in Lakeway
- Andrew von EschenbachMontgomery$3.2M
- Arun RaiHouston$920K
- Allen MoreyDallas$914K
- Donald GriffithHouston$732K
- Michael TrotterAustin$590K
- Vitaly MargulisDallas$555K
- Daniel SaltzsteinSan Antonio$547K
- Leroy JonesSan Antonio$506K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.